These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30723643)

  • 1. What Conditions Make Proton Beam Therapy Financially Viable in Western Canada?
    Smith WL; Smith CD; Patel S; Eisenstat DD; Quirk S; Mackenzie M; Olivotto IA
    Cureus; 2018 Nov; 10(11):e3644. PubMed ID: 30723643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?
    Patel S; Kostaras X; Parliament M; Olivotto IA; Nordal R; Aronyk K; Hagen N
    Curr Oncol; 2014 Oct; 21(5):251-62. PubMed ID: 25302033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-comparativeness of proton versus photon therapy.
    Verma V; Shah C; Rwigema JC; Solberg T; Zhu X; Simone CB
    Chin Clin Oncol; 2016 Aug; 5(4):56. PubMed ID: 27506804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton beam therapy and accountable care: the challenges ahead.
    Elnahal SM; Kerstiens J; Helsper RS; Zietman AL; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):e165-72. PubMed ID: 23265572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton therapy for early stage prostate cancer: is there a case?
    Chan TY; Tan PW; Tang JI
    Onco Targets Ther; 2016; 9():5577-86. PubMed ID: 27672328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Verma V; Mishra MV; Mehta MP
    Cancer; 2016 May; 122(10):1483-501. PubMed ID: 26828647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation.
    Sharma AM; Khairnar R; Kowalski ES; Remick J; Nichols EM; Mohindra P; Yock T; Regine W; Mishra MV
    Cureus; 2019 Sep; 11(9):e5703. PubMed ID: 31720171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis using lifetime attributable risk of proton beam therapy for pediatric medulloblastoma in Japan.
    Yoshimura T; Tamori H; Morii Y; Hashimoto T; Shimizu S; Ogasawara K
    J Radiat Res; 2021 Sep; ():. PubMed ID: 34590123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Canadian consensus recommendations for proton beam therapy access in Canada.
    Mitera G; Tsang D; McCurdy B; Goddard K; Ebacher A; Craig T; Greenland J; Kentish S; Koul R; Logie N; Morneau M; Morrison A; Pan L; Pantarotto J; Foxcroft S; Sussman J; Thompson R; Tyldesley S; Wright P; Hicks S; Brown E; Patel S;
    Radiother Oncol; 2022 Nov; 176():228-233. PubMed ID: 36228758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative costs of proton and X-ray radiation therapy.
    Goitein M; Jermann M
    Clin Oncol (R Coll Radiol); 2003 Feb; 15(1):S37-50. PubMed ID: 12602563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of proton therapy in treating base of skull chordoma.
    Austin AM; Douglass MJJ; Nguyen GT; Dalfsen R; Le H; Gorayski P; Tee H; Penniment M; Penfold SN
    Australas Phys Eng Sci Med; 2019 Dec; 42(4):1091-1098. PubMed ID: 31646441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hadrontherapy for cancer. An overview of HTA reports and ongoing studies.
    Jefferson T; Formoso G; Venturelli F; Vicentini M; Chiarolla E; Ballini L
    Recenti Prog Med; 2019 Dec; 110(12):566-586. PubMed ID: 31909760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doing poorly by doing good: the bottom line of proton therapy for children.
    Johnstone PA; Kerstiens J
    J Am Coll Radiol; 2014 Oct; 11(10):995-7. PubMed ID: 24881504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brainstem Toxicity in Pediatric Patients Treated with Protons Using a Single-vault Synchrocyclotron System.
    Orukari I; Perkins S; Zhao T; Huang J; Caruthers DF; Duriseti S
    Int J Part Ther; 2022; 9(1):12-17. PubMed ID: 35774490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients.
    Tamura M; Sakurai H; Mizumoto M; Kamizawa S; Murayama S; Yamashita H; Takao S; Suzuki R; Shirato H; Ito YM
    J Radiat Res; 2017 May; 58(3):363-371. PubMed ID: 27789564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.
    Allen AM; Pawlicki T; Dong L; Fourkal E; Buyyounouski M; Cengel K; Plastaras J; Bucci MK; Yock TI; Bonilla L; Price R; Harris EE; Konski AA
    Radiother Oncol; 2012 Apr; 103(1):8-11. PubMed ID: 22405807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton therapy expansion under current United States reimbursement models.
    Kerstiens J; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):235-40. PubMed ID: 24685152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma.
    Sher DJ; Tishler RB; Pham NL; Punglia RS
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):875-882. PubMed ID: 29976499
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.